Decreased acetylcholine release is correlated to memory impairment in the Tg2576 transgenic mouse model of Alzheimer's disease

Brain Research

Volumn 1249, Issue , 2009, Pages 222-228

  Watanabe, Takuya ^a   Yamagata, Norito ^a   Takasaki, Kotaro ^a   Sano, Kazunori ^a   Hayakawa, Kazuhide ^a   Katsurabayashi, Shutaro ^a   Egashira, Nobuaki ^a   Mishima, Kenichi ^a   Iwasaki, Katsunori ^a   Fujiwara, Michihiro ^a  

^a FUKUOKA UNIVERSITY   (Japan)

Author keywords

Acetylcholine; Alzheimer's disease; Memory; Transgenic

Indexed keywords

ACETYLCHOLINE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN;

ACETYLCHOLINE RELEASE; AGING; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLINERGIC SYNAPSE; CONTROLLED STUDY; HIPPOCAMPUS; MAZE TEST; MEMORY DISORDER; MOUSE; NONHUMAN; PRIORITY JOURNAL; SENILE PLAQUE; TRANSGENIC MOUSE;

ACETYLCHOLINE; AGING; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANALYSIS OF VARIANCE; ANIMALS; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; MAZE LEARNING; MEMORY DISORDERS; MICE; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; POTASSIUM; SENILE PLAQUES;

MUS; MUS MUSCULUS;

EID: 58049191392     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2008.10.029     Document Type: Article

References (33)

1. Abe E., Casamenti F., Giovannelli L., Scali C., and Pepeu G. Administration of amyloid beta-peptides into the medial septum of rats decreases acetylcholine release from hippocampus in vivo. Brain Res. 636 (1994) 162-164
2. Amaral D.G., and Kurz J. An analysis of the origins of the cholinergic and noncholinergic septal projections to the hippocampal formation of the rat. J. Comp. Neurol. 240 (1985) 37-59
3. Apelt J., Kumar A., and Schliebs R. Impairment of cholinergic neurotransmission in adult and aged transgenic Tg2576 mouse brain expressing the Swedish mutation of human beta-amyloid precursor protein. Brain Res. 953 (2002) 17-30
4. Bales K.R., Tzavara E.T., Wu S., Wade M.R., Bymaster F.P., Paul S.M., and Nomikos G.G. Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-A beta antibody. J. Clin. Invest. 116 (2006) 825-832
5. Borchelt D.R., Ratovitski T., van Lare J., Lee M.K., Gonzales V., Jenkins N.A., Copeland N.G., Price D.L., and Sisodia S.S. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 19 (1997) 939-945
6. Chauhan N.B., and Siegel G.J. Reversal of amyloid beta toxicity in Alzheimer's disease model Tg2576 by intraventricular antiamyloid beta antibody. J. Neurosci. Res. 69 (2002) 10-23
7. Cleary J.P., Walsh D.M., Hofmeister J.J., Shankar G.M., Kuskowski M.A., Selkoe D.J., and Ashe K.H. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat. Neurosci. 8 (2005) 79-84
8. Dong H., Csernansky C.A., Martin M.V., Bertchume A., Vallera D., and Csernansky J.G. Acetylcholinesterase inhibitors ameliorate behavioral deficits in the Tg2576 mouse model of Alzheimer's disease. Psychopharmacology (Berl) 181 (2005) 145-152
9. Fadda F., Cocco S., and Stancampiano R. Hippocampal acetylcholine release correlates with spatial learning performance in freely moving rats. Neuroreport 11 (2000) 2265-2269
10. Ferguson S.M., Brasnjo G., Hayashi M., Wölfel M., Collesi C., Giovedi S., Raimondi A., Gong L.W., Ariel P., Paradise S., O'toole E., Flavell R., Cremona O., Miesenböck G., Ryan T.A., and De Camilli P. A selective activity-dependent requirement for dynamin 1 in synaptic vesicle endocytosis. Science 316 (2007) 570-574
11. Fontana D.J., Inouye G.T., and Johnson R.M. Linopirdine (DuP 996) improves performance in several tests of learning and memory by modulation of cholinergic neurotransmission. Pharmacol. Biochem. Behav. 49 (1994) 1075-1082
12. Gau, J.T., Steinhilb, M.L., Kao, T.C., D'Amato, C.J., Gaut, J.R., Frey, K.A., Turner, R.S., 2002. Stable beta-secretase activity and presynaptic cholinergic markers during progressive central nervous system amyloidogenesis in Tg2576 mice. Am. J. Pathol. 160, 731-738.
13. Geula C., Wu C.K., Saroff D., Lorenzo A., Yuan M., and Yankner B.A. Aging renders the brain vulnerable to amyloid beta-protein neurotoxicity. Nat. Med. 4 (1998) 827-831
14. Glabe C.G. Conformation-dependent antibodies target diseases of protein misfolding. Trends Biochem. Sci. 29 (2004) 542-547
15. Hiramatsu M., Miwa M., Hashimoto K., Kawai S., and Nomura N. Nociceptin/orphanin FQ reverses mecamylamine-induced learning and memory impairment as well as decrease in hippocampal acetylcholine release in the rat. Brain Res. 1195 (2008) 96-103
16. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., and Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274 (1996) 99-102
17. Kelly B.L., Vassar R., and Ferreira A. Beta-amyloid-induced dynamin 1 depletion in hippocampal neurons. A potential mechanism for early cognitive decline in Alzheimer disease. J. Biol. Chem. 980 (2005) 31746-31753
18. Lorenzo A., and Yankner B.A. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 12243-12247
19. Melo J.B., Agostinho P., and Oliveira C.R. Amyloid beta-peptide 25-35 reduces [3H]acetylcholine release in retinal neurons. Involvement of metabolic dysfunction. Amyloid 2002 (2002) 221-228
20. Mishima K., Iwasaki K., Tsukikawa H., Matsumoto Y., Egashira N., Abe K., Egawa T., and Fujiwara M. The scopolamine-induced impairment of spatial cognition parallels the acetylcholine release in the ventral hippocampus in rats. Jpn. J. Pharmacol. 84 (2000) 163-173
21. Nakamura S., Murayama N., Noshita T., Annoura H., and Ohno T. Progressive brain dysfunction following intracerebroventricular infusion of beta(1-42)-amyloid peptide. Brain Res. 912 (2001) 128-136
22. Olton D.S., and Samuelson D.S. Remembrance of places past: spatial memory in rats. J. Exp. Psychol. Anim. Behav. Process 2 (1976) 97-116
23. Ovsepian S.V., Anwyl R., and Rowan M.J. Endogenous acetylcholine lowers the threshold for long-term potentiation induction in the CA1 area through muscarinic receptor activation: in vivo study. Eur. J. Neurosci. 20 (2004) 1267-1275
24. Pike C.J., Walencewicz A.J., Glabe C.G., and Cotman C.W. In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res. 563 (1991) 311-314
25. Sigurdsson E.M., Knudsen E., Asuni A., Fitzer-Attas C., Sage D., Quartermain D., Goni F., Frangione B., and Wisniewski T. An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-beta derivatives. J. Neurosci. 24 (2004) 6277-6282
26. Vickroy T.W. Presynaptic cholinergic actions by the putative cognitive enhancing agent DuP 996. J. Pharmacol. Exp. Ther. 264 (1993) 910-917
27. Waite, J.J., Chen, A.D., 2001. Differential changes in rat cholinergic parameters subsequent to immunotoxic lesion of the basal forebrain nuclei. Brain Res. 918, 113-120.
28. Walsh T.J., Herzog C.D., Gandhi C., Stackman R.W., and Wiley R.G. Injection of IgG 192-saporin into the medial septum produces cholinergic hypofunction and dose-dependent working memory deficits. Brain Res. 726 (1996) 69-79
29. Walsh D.M., Klyubin I., Fadeeva J.V., Rowan M.J., and Selkoe D.J. Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. Biochem. Soc. Trans. 30 (2002) 552-557
30. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., and Selkoe D.J. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416 (2002) 535-539
31. Watanabe T., Iwasaki K., Ishikane S., Naitou T., Yoshimitsu Y., Yamagata N., Ozdemir M.B., Takasaki K., Egashira N., Mishima K., and Fujiwara M. Spatial memory impairment without apoptosis induced by the combination of beta-amyloid oligomers and cerebral ischemia is related to decreased acetylcholine release in rats. J. Pharmacol. Sci. 106 (2008) 84-91
32. Westerman, M.A., Cooper-Blacketer, D., Mariash, A., Kotilinek, L., Kawarabayashi, T., Younkin, L.H., Carlson, G.A., Younkin, S.G., Ashe, K.H., 2002. The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J. Neurosci. 22, 1858-1867.
33. Woodside B.L., Borroni A.M., Hammonds M.D., and Teyler T.J. NMDA receptors and voltage-dependent calcium channels mediate different aspects of acquisition and retention of a spatial memory task. Neurobiol. Learn Mem. 81 (2004) 105-114